DEXTENZA
NDA- Indications
- Ocular inflammation, Ocular pain, Allergic conjunctivitis
Company intelligence / Profile preview
AffaMed Therapeutics
Shanghai, Chinaaffamed.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- NDA
01
Overview
AffaMed has advanced several assets to late-stage clinical development in ophthalmology and CNS. Notably, DEXTENZA received NDA acceptance in Singapore for post-surgical ocular inflammation/pain and allergic conjunctivitis. Positive real-world data reported for DEXTENZA after cataract surgery in China. Risuteganib approved for clinical trials in China targeting intermediate dry AMD.
The company also develops digital therapeutics through its subsidiary "AffaMed Digital" focused on evidence-based solutions for neurological/psychiatric/ophthalmic conditions.
Pipeline includes small molecules, biosimilars/biologics, medical devices such as intraocular lenses.
Merger with EverInsight expanded the pipeline into CNS.
Multiple programs are at Phase II/III or NDA/BLA stages.
Raised over $250M since founding in two rounds of financing.
Key leadership includes Dr. Dayao Zhao as CEO.
Focused on Greater China but operates globally.
- Therapeutic areas
- OphthalmologyPsychiatryNeurology
- Modalities
- Small moleculesBiosimilarsFab fragmentsBiological productsDigital therapeuticsMedical devices (e.g., intraocular lenses)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Kissei Pharmaceutical Co., Ltd.: exclusive licensing agreement for KDT‑3594/Parkinson’s agent [6].Licensing partnerships with global biopharma companies to augment portfolio [6].Merged with EverInsight Therapeutics [6].
Beyond the preview
Go deeper on AffaMed Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AffaMed Therapeutics.